Drug Type Synthetic peptide |
Synonyms- |
Target |
Action- |
Mechanism CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists), EGFRvIII agonists(Epidermal growth factor receptor variant III agonists), IL-13Rα2 agonists(Interleukin-13 receptor subunit alpha-2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Discovery | - | 24 Oct 2024 |





